PL2437736T3 - Systemy dostarczania leków - Google Patents

Systemy dostarczania leków

Info

Publication number
PL2437736T3
PL2437736T3 PL10730357T PL10730357T PL2437736T3 PL 2437736 T3 PL2437736 T3 PL 2437736T3 PL 10730357 T PL10730357 T PL 10730357T PL 10730357 T PL10730357 T PL 10730357T PL 2437736 T3 PL2437736 T3 PL 2437736T3
Authority
PL
Poland
Prior art keywords
drug delivery
delivery systems
systems
drug
delivery
Prior art date
Application number
PL10730357T
Other languages
English (en)
Inventor
Mauro Magnani
Luigia Rossi
Sara Biagiotti
Marzia Bianchi
Original Assignee
Erydel Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Erydel Spa filed Critical Erydel Spa
Publication of PL2437736T3 publication Critical patent/PL2437736T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0634Cells from the blood or the immune system
    • C12N5/0641Erythrocytes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14Blood; Artificial blood
    • A61K35/18Erythrocytes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13Cyclosporins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/02Antidotes
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00Drug, bio-affecting and body treating compositions
    • Y10S424/81Drug, bio-affecting and body treating compositions involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, immunotolerance, or anergy
PL10730357T 2009-06-05 2010-06-07 Systemy dostarczania leków PL2437736T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0909754.4A GB0909754D0 (en) 2009-06-05 2009-06-05 Drug delivery systems
PCT/EP2010/003783 WO2010145849A2 (en) 2009-06-05 2010-06-07 Drug delivery systems
EP10730357.0A EP2437736B1 (en) 2009-06-05 2010-06-07 Drug delivery systems

Publications (1)

Publication Number Publication Date
PL2437736T3 true PL2437736T3 (pl) 2018-01-31

Family

ID=40937008

Family Applications (1)

Application Number Title Priority Date Filing Date
PL10730357T PL2437736T3 (pl) 2009-06-05 2010-06-07 Systemy dostarczania leków

Country Status (11)

Country Link
US (1) US8734787B2 (pl)
EP (1) EP2437736B1 (pl)
AU (1) AU2010262090B2 (pl)
CA (1) CA2763695C (pl)
DK (1) DK2437736T3 (pl)
ES (1) ES2645775T3 (pl)
GB (1) GB0909754D0 (pl)
NO (1) NO2437736T3 (pl)
NZ (1) NZ596813A (pl)
PL (1) PL2437736T3 (pl)
WO (1) WO2010145849A2 (pl)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011051346A1 (en) * 2009-10-27 2011-05-05 Erytech Pharma Composition to induce specific immune tolerance
ITBO20100256A1 (it) * 2010-04-26 2011-10-27 Erydel Spa Metodo per incapsulare almeno un composto ad uso terapeutico e/o diagnostico all'interno di eritrociti
BR112014009346B1 (pt) 2011-10-17 2020-09-15 Massachusetts Institute Of Technology Entrega intracelular
ES2865107T3 (es) 2013-08-16 2021-10-15 Massachusetts Inst Technology Administración selectiva de material a células
KR20230098928A (ko) 2014-10-31 2023-07-04 메사추세츠 인스티튜트 오브 테크놀로지 면역 세포로의 생체분자의 전달
JP6846345B2 (ja) 2014-11-14 2021-03-24 マサチューセッツ インスティテュート オブ テクノロジー 破壊及び場による細胞への化合物及び組成物の送達
CN107250373A (zh) 2015-01-12 2017-10-13 麻省理工学院 通过微流体递送实现的基因编辑
WO2017008063A1 (en) 2015-07-09 2017-01-12 Massachusetts Institute Of Technology Delivery of materials to anucleate cells
WO2017041051A1 (en) 2015-09-04 2017-03-09 Sqz Biotechnologies Company Intracellular delivery of biomolecules to cells comprising a cell wall
US11123441B2 (en) 2016-10-04 2021-09-21 The Trustees Of The University Of Pennsylvania Methods and compositions for drug delivery

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI111730B (fi) * 1990-11-02 2003-09-15 Novartis Ag Menetelmä ei-immunosuppressiivisen syklosporiinin valmistamiseksi
US5482945A (en) * 1992-12-22 1996-01-09 American Home Products Corporation Innovative technique for immunosuppression involving administration of rapamycin loaded formed blood elements
AU7843394A (en) * 1993-10-27 1995-05-22 Regents Of The University Of California, The Antiviral compounds
DE69732225T2 (de) 1997-05-05 2005-06-23 Dideco S.R.L., Mirandola Verfahren zur Verkapselung von biologisch aktiven Stoffen in Erythrocyten und Gerät dafür
US6887842B1 (en) * 1999-11-19 2005-05-03 The Board Of Trustees Of The Leland Stanford Junior University Modulating a pharmacokinetic property of a drug by administering a bifunctional molecule containing the drug
WO2003073993A2 (en) * 2002-03-01 2003-09-12 Colb Mark A Binding of red blood cell to exposed subendothelial surfaces to impede platelet deposition thereon and/or for use in targeted drug delivery thereto
US7465298B2 (en) * 2002-06-28 2008-12-16 Mercator Medsystems, Inc. Methods and systems for delivering liquid substances to tissues surrounding body lumens
GB2439747A (en) 2006-07-03 2008-01-09 Uni Degli Studi Di Urbino Carl Delivery of contrasting agents for magnetic resonance imaging
US20090053245A1 (en) * 2007-05-29 2009-02-26 Mutz Mitchell W Pharmacokinetics and Efficacy of Anti-Angiogenic Drugs and Drugs Treating Diseases of the Blood

Also Published As

Publication number Publication date
NZ596813A (en) 2013-12-20
WO2010145849A3 (en) 2011-12-15
EP2437736A2 (en) 2012-04-11
DK2437736T3 (da) 2017-11-13
US20120141540A1 (en) 2012-06-07
CA2763695A1 (en) 2010-12-23
AU2010262090B2 (en) 2016-08-25
CA2763695C (en) 2016-09-13
WO2010145849A2 (en) 2010-12-23
AU2010262090A1 (en) 2011-12-15
ES2645775T3 (es) 2017-12-07
US8734787B2 (en) 2014-05-27
NO2437736T3 (pl) 2017-12-30
GB0909754D0 (en) 2009-07-22
EP2437736B1 (en) 2017-08-02

Similar Documents

Publication Publication Date Title
HK1258442A1 (zh) 藥劑遞送系統
HK1201223A1 (en) Drug delivery management systems
PL2398500T3 (pl) System dostarczania leków na bazie glutationu
ZA201101737B (en) Progestin-containing drug delivery system
PL2654864T3 (pl) System dostarczania leku
HK1166731A1 (en) Drug delivery device
HK1164759A1 (en) Medicament delivery devices
HK1164758A1 (en) Medicament delivery devices
HK1164176A1 (en) Medicament delivery devices
EP2516671A4 (en) SYSTEMS FOR MANAGING DRUG DELIVERY DEVICES
GB0903810D0 (en) Delivery system
IL215219A0 (en) Drug delivery device
IL218839A0 (en) Drug delivery device
PL2401027T3 (pl) Układ do interwencyjnego dostarczania leku
EP2481399A4 (en) ACTIVE COMPOSITION SYSTEM WITH LONG-TERM EFFECT
EP2382947A4 (en) STENT DELIVERY SYSTEM
IL214099A0 (en) Conjugate based systems for controlled drug delivery
HK1166728A1 (en) Drug delivery device
EP2431009A4 (en) STENT LAYING SYSTEM
ZA201106668B (en) Zoo-technical drug delivery device
PL2506909T3 (pl) Urządzenie do podawania leków
PL2437736T3 (pl) Systemy dostarczania leków
IL217416A0 (en) Drug delivery delivery device
GB201006818D0 (en) Drug delivery
GB201018750D0 (en) Drug delivery system